Last reviewed · How we verify
Candesartan and Hydrochlorothiazide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Candesartan and Hydrochlorothiazide (Candesartan and Hydrochlorothiazide) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Candesartan and Hydrochlorothiazide TARGET | Candesartan and Hydrochlorothiazide | Takeda | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Candesartan and Hydrochlorothiazide CI watch — RSS
- Candesartan and Hydrochlorothiazide CI watch — Atom
- Candesartan and Hydrochlorothiazide CI watch — JSON
- Candesartan and Hydrochlorothiazide alone — RSS
Cite this brief
Drug Landscape (2026). Candesartan and Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-and-hydrochlorothiazide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab